VANDA PHARMACEUTICALS INC (VNDA) 9.53 -0.14 (-1.45%)
9.53 -0.14 (-1.45%)
US9216591084 - Common Stock - After market: 9.53 0 (0%)
Fundamental Rating
We assign a fundamental rating of 4 out of 10 to VNDA. VNDA was compared to 638 industry peers in the Biotechnology industry. Both the profitability and the financial health of VNDA get a neutral evaluation. Nothing too spectacular is happening here. VNDA has a expensive valuation and it also scores bad on growth
Profitability
Profitability Rating
VNDA has a Return On Assets of 1.80%. This is amongst the best returns in the industry. The industry average is -41.19%. VNDA outperforms 93% of its industry peers.
VNDA has a Profit Margin of 4.18%. This is amongst the best returns in the industry. The industry average is -408.39%. VNDA outperforms 89% of its industry peers.
The Piotroski-F score of VNDA is 5.00. This is a neutral score and indicates average health and profitability for VNDA.
VNDA's Return On Equity of 2.16% is worse than the rest of the industry. The industry average Return On Equity is 20.55%. 92% of the industry peers have a better Return On Equity.
VS Industry
ROA (1.8%) VS Industry: 93% outperformed.
-1,441.42
115.38
ROE (2.16%) VS Industry: 8% outperformed.
0.23
535.19
Profit Margin (4.18%) VS Industry: 89% outperformed.
-1,173,705.71
8,610.80
Valuation
Valuation Rating
When comparing the price book ratio of VNDA to the average industry price book ratio of 1.59, VNDA is valued rather cheaply.
With a price book ratio of 1.06, VNDA is valued correctly.
The Price/Earnings Ratio is 47.65, which means the current valuation is very expensive for VNDA.
Compared to an average industry Price/Earning Ratio of 12.14, VNDA is valued more expensive than its industry peers. On top of this 90% of the companies listed in the same industry are cheaper than VNDA!
The Forward Price/Earnings Ratio of 66.74 indicates a quite expensive current valuation of VNDA.
Compared to an average industry Enterprise Value to EBITDA ratio of 0.85, VNDA is valued more expensive than its industry peers.
VS Industry
Price/Earnings (47.65) VS Industry: 10% outperformed.
193.40
0.16
Price/Book (1.06) VS Industry: 62% outperformed.
162.47
0.08
Enterprise Value/ EBITDA (2.78) VS Industry: 21% outperformed.
4,208.87
0.01
Growth
Growth Rating
The Revenue has been growing by 12.97% on average over the past 5 years. This is quite good.
The Earnings Per Share has been growing slightly by 7.26% on average over the past 5 years.
Based on estimates for the next 5 years, VNDA will show a decrease in Earnings Per Share. The EPS will decrease by -3.14% on average per year.
Looking at the last year, VNDA shows a small growth in Revenue. The Revenue has grown by 1.61% in the last year.
Based on estimates for the next 5 years, VNDA will show a small growth in Revenue. The Revenue will grow by 0.48% on average per year.
VNDA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -65.52%.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | 7.26% | -65.52% | -68.34% | -50.38% | -21.98% | -3.14% |
| Revenue | 12.97% | 11.64% | 1.61% | -2.15% | -0.1% | 0.37% | 0.48% |
Health
Health Rating
A Current Ratio of 5.62 indicates that VNDA has no problem at all paying its short term obligations.
A Quick Ratio of 5.60 indicates that VNDA has no problem at all paying its short term obligations.
An Altman-Z score of 4.17 indicates that VNDA is not in any danger for bankruptcy at the moment.
The Altman-Z score of VNDA is much better than the industry average of -0.10.
The Current Ratio is in line with the industry averages, which is at 6.52.
The Quick Ratio is in line with the industry averages, which is at 6.48.
The Debt to Equity ratio of VNDA is in line with the industry averages.
The Piotroski-F score of VNDA is 5.00. This is a neutral score and indicates average health and profitability for VNDA.
VS Industry
Debt/Equity (0) VS Industry: 43% outperformed.
18.24
0.00
Quick Ratio (5.6) VS Industry: 45% outperformed.
0.03
399.16
Current Ratio (5.62) VS Industry: 44% outperformed.
0.08
401.12
Altman-Z (4.17) VS Industry: 73% outperformed.
-1,821.48
293.92
Dividend
Dividend Rating
No dividends for VNDA!.
VANDA PHARMACEUTICALS INC9.53
NASDAQ:VNDA (9/26/2022, 7:22:49 PM)-0.14 (-1.45%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Biotechnology | ||
| Earnings (Last) | 08-03 2022-08-03/amc | Earnings (Next) | 11-01 2022-11-01 |
| Ins Owners | 3.79% | Inst Owners | 103.92% |
| Market Cap | 538.35M | Analysts | 43.33 |
| PE | 47.65 | Fwd PE | 66.74 |
| PEG (NY) | N/A | PEG (5Y) | N/A |
| P/S | 2.05 | P/B | 1.06 |
| EV/EBITDA | 2.78 | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
| EPS 1Y | -65.52% | EPS 3Y | 7.26% |
| EPS 5Y | N/A | EPS growth Q2Q | -70.59% |
| EPS Next Y | -68.34% | EPS Next 2Y | -50.38% |
| EPS Next 3Y | -21.98% | EPS Next 5Y | -3.14% |
| Revenue growth 1Y | 1.61% | Revenue growth 3Y | 11.64% |
| Revenue growth 5Y | 12.97% | Revenue growth Q2Q | -5.17% |
| Revenue Next Year | -2.15% | Revenue Next 2Y | -0.1% |
| Revenue Next 3Y | 0.37% | Revenue Next 5Y | 0.48% |
| Current Ratio | 5.62 | Quick Ratio | 5.6 |
| Altman-Z | 4.17 | F-Score | 5 |
| Debt/Equity | 0 | ||
| ROA | 1.8% | ROE | 2.16% |
| ROIC | 5.32% | ROICg | 5.12% |
| PM | 4.18 | OM | 13.34 |
| Asset Turnover | 0.43 | ||
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA